Department of Pharmaceutics, Utrecht Institute of Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands.
University of Vienna, Department of Pharmaceutical Chemistry, Althanstraße 14, Vienna, Austria.
Int J Pharm. 2018 Sep 15;548(2):793-802. doi: 10.1016/j.ijpharm.2017.12.035. Epub 2017 Dec 21.
There is a very large variety in the types of nanoparticulate lipid formulations for oligonucleotides, and remarkably, also a very large heterogeneity in the methods that are used for analyzing oligonucleotide load, encapsulation efficiency and oligonucleotide release. Furthermore, a literature survey showed that the extent to which these procedures are reported in scientific literature varies greatly, with some of them not even reporting any quantification at all. This greatly hampers the reproducibility of nanoparticle preparation between different researchers and between different laboratories, which slows down the clinical translation of such nanomedicines. In this work, a standardized extraction method from liposomes is proposed, in which potential contaminants from the carrier are removed by a simple extraction of the oligonucleotides. These extracts were then analyzed with seven commonly used methods for oligonucleotide quantification, including several absorbance based methods and the most commonly applied dye binding assay. Strikingly, differences in absolute values up to fourfold were found when the same sample was analyzed using different methods which should be taken into consideration when reports using different methods are compared. Furthermore, these results indicate that the most commonly applied method, the dye binding assay, may -without adaptations- not be suitable for short oligonucleotides like siRNAs. The found differences in quantification methods as described here underscore the need for proper documentation of methods to correctly interpret published results, which -with regard to oligonucleotide analysis- is currently lacking in many reports.
用于寡核苷酸的纳米颗粒脂质制剂的种类非常多,令人惊讶的是,用于分析寡核苷酸负载、包封效率和寡核苷酸释放的方法也非常多样化。此外,文献调查表明,这些程序在科学文献中的报告程度差异很大,其中一些甚至根本没有报告任何定量信息。这极大地阻碍了不同研究人员和不同实验室之间纳米颗粒制备的可重复性,从而减缓了此类纳米药物的临床转化。在这项工作中,提出了一种从脂质体中进行标准化提取的方法,其中通过简单地提取寡核苷酸来去除载体中的潜在污染物。然后,使用七种常用的寡核苷酸定量方法对这些提取物进行分析,包括几种基于吸光度的方法和最常用的染料结合测定法。令人惊讶的是,当使用不同的方法分析同一样品时,发现了绝对值高达四倍的差异,当比较使用不同方法的报告时,应该考虑到这些差异。此外,这些结果表明,最常用的方法,即染料结合测定法,可能(如果不进行调整)不适合像 siRNA 这样的短寡核苷酸。这里描述的定量方法之间的差异强调了正确解释已发表结果需要适当记录方法的必要性,而在寡核苷酸分析方面,目前许多报告都缺乏这种记录。